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Abstract
Background: Human cytomegalovirus (HCMV) infections are a major cause of morbidity and mortality among immunocompro-
mised patients. Prolonged antiviral therapy is a cause of mutation and drug resistance in the HCMV genome.
Objectives: The aim of this study was to identify resistance to ganciclovir (GCV) in Iranian immunosuppressed patients at two
different stages of the disease: early (before GCV is initiated) and late (after six months of GCV therapy).
Patients and Methods: In this study, 87 specimens from Iranian patients were amplified using nested PCR amplification of the UL97
gene. Sequence analyses of products were performed for identifying the mutated codons.
Results: The present study show that the most frequent GCV-resistant mutations occurred in codons A594V (26.43%), H520Q (18.39%),
and M460V (13.79%), consequently occurring at a low frequency in the L595S (2.29%), E596G (1.14%), and Del 594 (1.14%) codons, and
with intermediate frequency in the C592G (10.34%), M460I (9.19%), and C603W (6.89%) codons. We describe for the first time a new
GCV-resistance mutation, the deletion of codon 594, in the UL97 gene of Iranian HCMV patients after GCV therapy, following renal
transplantation.
Conclusions: The findings of the present study can be utilized to detect GCV resistance patterns among Iranian immunocompro-
mised patients and to treat HCMV infections accordingly.
Keywords: UL97 Protein, Human Cytomegalovirus, Ganciclovir, Iran
1. Background
Human cytomegalovirus (HCMV) infections are a ma-
jor cause of morbidity and mortality among immunocom-
promised patients. Susceptible groups include renal trans-
plant recipients, bone marrow recipients, and AIDS pa-
tients (1, 2). Hence, early diagnosis for the accurate treat-
ment of HCMV is especially necessary to avoid poor clinical
outcomes (3-6). Antiviral agents are used in the manage-
ment of HCMV infections. Currently, the most common an-
tiviral agents include ganciclovir (GCV), foscarnet, and cid-
ofovir. These agents inhibit HCMV DNA synthesis by sup-
pressing the DNA polymerase of the causative virus. Hu-
man cytomegalovirus infections usually require long-term
treatment with antiviral agents for efficacy against the in-
fective viruses. This can give rise to resistant strains of
HCMV (7-10). Resistance to GCV has been evaluated by many
researchers because this agent is used as the first-line treat-
ment in 90% of HCMV patients (11).
Ganciclovir, a nucleoside analogue, must be phospho-
rylated to exert antiviral activity as an inhibitor of viral
DNA polymerase UL54. The UL97 kinase, a virus-encoded
product, activates the drug by monophosphorylation (12-
17). HCMV resistance to GCV is mainly associated with the
presence of mutations within UL97, DNA polymerase, or
both viral genes (12, 18-25). Although mutations confer-
ring GCV resistance have been mapped in both genes, the
majority of the mutations appear in the UL97 gene, rather
than as UL54 gene mutations (26). In the last two decades,
several methods based on phenotypic testing have been
described for the detection of HCMV-resistant mutations,
such as the plaque reduction assay, ELISA, and DNA hy-
bridization assays (27-29). However, these tests are burden-
some, time-consuming, and labor-intensive (30). There-
fore, there is an increasing need for early detection of the
emerging mutants (31, 32).
2. Objectives
The purpose of the present study was the examination
of GCV-resistant HCMV in Iranian immunosuppressed pa-
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tients, before and after treatment.
3. Patients and Methods
3.1. Patients
A total of 87 specimens from Iranian patients were tar-
geted in the present study. Clinical isolates from 48 bone
marrow transplant patients and 39 renal transplant pa-
tients with suspected HCMV infections were identified and
sent to the Keyvan virology specialty laboratory (KVSL) for
molecular examination of the UL97 gene. The specimens
were collected at two different stages of the disease: early
(before GCV was initiated) and late (after six months of
GCV therapy). All of the selected patients completed ques-
tionnaires and informed consent forms for participation
in this study.
3.2. Nucleic Acid Extraction
Plasma samples (200 µL) were used for DNA extrac-
tion using the QIAamp DNA blood mini kit (Qiagen, USA).
The extractions were carried out according to the manufac-
turer’s instructions.
3.3. Detection of HCMV in Specimens
Extracted DNA of plasma samples was subjected
to TaqMan® real-time PCR targeting the UL83 gene,
with the primers and probe proposed by Khansarine-
jad et al. (33). The sequence of the forward primer
was 5′-TGAACATCCCCAGCATCAACG-3′, of the reverse
primer was 5′-CAGTCCCGAGACMGTGAGAC-3′, and of
the probe was 5′-FAM TGCCACATCTGCTTGCCCGACGC-
BHQ1-3´. These primers and probe amplified the 137
bp segment of the UL83 gene in HCMV. Internal con-
trol of DNA extraction and PCR amplification was con-
ducted by amplification of the human β globin gene.
The primers consisted of the following sequences: for-
ward primer: 5′-CAGAGCCATCTATTGCTTAC-3′, reverse
primer: 5′-CATGGTGTCTGTTTGAGGTT-3′, and probe: 5′-
JOE-ACACAACTGTGTTCACTAGC-BHQ1-3′ (34). All primers
and probes were purchased from Bioneer Co., Ltd. (Dae-
jeon, Korea). Real-time PCR was performed with TaqMan
universal master mix (Takara Bio, Shiga, Japan). DNA was
added to a 25 PCR mixture containing 12.5 µL of TaqMan
universal PCR master mix, 300 nM of each primer, and 200
nM of probe. The reaction consisted of 10 minutes at 95°C,
followed by 40 cycles of amplification, including 15 s at
95°C and 1 minute at 60°C.
3.4. Analysis of the UL97 Gene
Specific regions of the UL97 gene of HCMV in
the early and late samples were amplified using
nested PCR, as defined by Benzi et al. (35). The first
round was done with the following primers: UL97-
F1 (5′-GTTTCATCACGACCAGTGGA-3′) and UL97-R1 (5′-
GGTCCTCCTCGCAGATTATG-3′). The second round was
carried out with UL97-F2 (5′-TCATCACGACCAGTGGAAGCT-
3′) and UL97-R2 (5′-GCGACACGAGGACATCTTGG-3′). The
UL97 fragment was amplified using 1.5 mM MgCl2, 0.2 mM
dNTP, 1 U Taq DNA polymerase, 10X PCR buffer (Kowsar
Biotech Co., Tehran, Iran), 300 nM of each primer (Bioneer
Co., Daejeon, Korea), and 50 ng genomic DNA of HCMV. The
thermal cycler was run at 94°C for 30 seconds, 52°C for 40
seconds, and 72°C for 2 minutes for 40 cycles, and 72°C for
7 minutes. All of the nested PCR products were subjected
to direct Sanger dideoxy DNA sequencing using internal
primers of the UL97 gene (UL97-F2 and UL97-R2) (Bioneer
Co., Daejeon, Korea). The results of the sequencing were
analyzed with the CLC sequence viewer, version 6.4 (CLC
Bio Co., Aarhus, Denmark).
4. Results
The fluorescent signals were observed in the FAM and
JOE channels related to the UL83 and β globin genes, re-
spectively. These data showed specific amplification of
UL83 and β globin genes by real-time PCR amplification of
genomic DNA of all samples. To confirm the specificity of
the PCR and the real-time PCR assay, genomic DNA from
other human herpesviruses (herpes simplex virus types
1 and 2, varicella-zoster virus, and human herpesvirus 6)
was amplified. The negative results after amplification of
all samples proved the specificity, and there was no cross-
reactivity of all assays (data not shown).
Specific nested PCR primers amplified the vulnerable
region in the UL97 gene. The binding site of primers on
the UL97 gene of HCMV (2124 bp) were nucleotide numbers
1254 - 1273, 2070 - 2089, 1257 - 1277, and 1916 - 1935 for UL97-F1,
UL97-R1, UL97-F2, UL97-R2, respectively. Accordingly, in the
first round of the assay, the expected 836-bp PCR products
were exhibited. The presence of the expected 679-bp band
in the second round of the assay proved the specific ampli-
fication of the UL97 gene during the nested PCR reaction
(Figure 1).
Based on the previous report, the predominant codon
numbers in the UL97 gene of HCMV corresponding
to GCV resistance have been reported: L405P, M460I,
M460T, M460V, V466G, H520Q, ACRA591-594Del4, 591-
607Del, C592G, A594E, A594G, A594P, A594T, A594V, L595F,
L595S, L595W, L595Del, 595-603Del, E596G, G598S, K599T,
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Figure 1. Gel Electrophoresis of Nested PCR Products of the UL97 Gene
M, 100 bp marker; 1, HCMV positive control; 2, Iranian HCMV sample; 3, negative con-
trol.
L600Del, T601Del, 601-603Del, C603R, C603S, C603W,
C607F, and C607Y (36). In order to analyze the sequenced
PCR product of the UL97 gene, a series accession number
from the GenBank database was selected. Then, using the
CLC Sequence Viewer software, the unknown sequences
of the UL97 gene from Iranian immunosuppressed pa-
tients were aligned with wild-type and mutant nucleotide
sequences.
The codon locations of the samples were evaluated
with the reported mutant codon, which has been pub-
lished previously (12, 31, 35, 36). Of the 87 samples, only one
(1.14%) point mutation occurred in the early-phase analysis
of the samples, but many mutations occurred after treat-
ment with GCV: A594V (26.46%), H520Q (18.39%), M460V
(13.79%), C592G (10.34%), M460I (9.19%), C603W (6.89%),
L595S (2.29%), E596G (1.14%), and Del 594 (1.14%) (Figure 2).
Comparison of the early and late sequences of the UL97
gene exhibited the presence of point mutations in the spe-
cific codon of the UL97 gene mainly after drug consump-
tion in the late phase. In addition, for the first time among
immunocompromised patients in Iran, a new mutation
(Del codon 594) was discovered in the HCMV UL97 gene in a
patient who had undergone renal transplantation. The fre-
quencies of early and late mutations of the UL97 gene are











































Figure 2. Percentage of UL97 Gene Mutations in HCMV Infection Samples in Iran
5. Discussion
Prolonged GCV therapy in transplant patients is the
main cause of mutations occurring in the UL97 gene and
the subsequent emergence of GCV resistance. One of the
most difficult therapeutic challenges is to determine the
wild-type or mutant viruses in transplant patients (37, 38).
Mutations of M460V, M460I, H520Q, A594V, L595S, L595F,
C603W, and C607Y for resistance of HCMV to GCV have
already been reported. In addition, N510S, A590T, A591V,
A591D, C592G, L595W, L595T, E596G, E596D, N597I, G598V,
K599M, C603Y, A606D, and V665I have also been discov-
ered among clinically GCV-resistant isolates (39). Our study
results showed that the early-phase analysis of mutations
identified only one renal transplant patient’s sample as
positive for the presence of A594V. This suggests that the
presence of resistant viruses is weak in the early stages
of the disease, whereas a high frequency of the mutated
viruses can be detected in the late analysis of mutations.
Erice et al. elucidated no evidence so far for GCV resis-
tance of A591V, C592G, L595W, L595T, E596G, N597I, G598V,
K599M, C603Y, A606D, and V665I. We found one point mu-
tation of E596G among our clinical specimens with resis-
tance to HCMV (39). Hantz et al. evaluated 18 infected pa-
tients, and discovered high-level resistance mutations of
M460V (3/17), A594V (2/17), L595S (6/17), and L595F (2/17), and
a 12-codon deletion (Del 591–603). They also found low-level
resistance mutations of C592G, A594P, and C603W in the
UL97 gene (11). Our data also support the fact that most
of the mutations are seen in the UL97 gene, with a high
frequency in the A594V (23/87), H520Q (16/87), and M460V
(12/87) codons.
Some deletions have previously been explained in an
immunocompromised patient in association with clinical
resistance to GCV, in the codons of the UL97 gene. Hantz
et al. discovered a novel GCV-resistance mutation (a dele-
Jundishapur J Microbiol. 2016; 9(5):e31733. 3
Keyvani H et al.
Table 1. List of Accession Numbers (Wild-Type and Mutant Sequences) and Frequency of Early and Late Mutations Related to the UL97 Gene
CN WTN MN WTAN MAN EAM LAM
H520Q CAT, CAC CAA, CAG AY642448 AY642438 0 16
L595S CTT, CTC, CTA, CTG TCT, TCC, TCA, TCG HQ158765 AY642437 0 2
M460V ATG GTT, GTC, GTA, GTG AY642435 HCU07356 0 12
C603W TGT, TGC TGG AY642443 AY642451 0 6
E596G GAA, GAG GGT, GGC, GGA, GGG AF345351 - 0 1
A594V GCT, GCC, GCA, GCG GTT, GTC, GTA, GTG AY642439 HM208324 1 23
M460I ATG ATT, ATC, ATA HQ158775 AY642447 0 8
C592G TGT, TGC GGT, GGC, GGA, GGG HQ158791 HM352648 0 9
Del 594 GCG - KC664775 KM081676 0 1
No mutation - - BK000394 - 0 1
Abbrevatins: CN, codon number; EAM, early analysis of mutation (n); LAM, late analysis of mutation (n); MAN, mutant accession number; MN, mutant nucleotide; WTAN,
wild-type accession number; WTN, wild-type nucleotide.
tion of codon 601 of the UL97 gene) in kidney transplant
patients (12). Marfori et al. found a new viral UL97 muta-
tion (deletion of codons 601 - 603) in stem cell transplant
recipients (40). Gentry et al. discovered that a deletion in
base pair 498 of UL97 is responsible for drug resistance in
the HCMV virus (41). Chou et al. reported a deletion muta-
tion (codons 595 to 603) in the UL97 gene (16). For the first
time, our study presents a description of a UL97 codon 594
deletion in a GCV-resistant HCMV isolate among Iranian
immunocompromised patients. This deletion emerged in
a renal transplant recipient after six months of GCV treat-
ment for HCMV infection.
5.1. Conclusion
The results of our study support the hypothesis of
a high prevalence of A594V, M460V, and H520Q muta-
tions, low rates of point mutations in the L595S and E596G
codons, and an intermediate prevalence of the C603W,
M460I, and C592G mutations. Furthermore, the presence
of Del 594 in Iranian immunosuppressed patients was also
observed. The present study demonstrates an effective
method for the early detection of mutations that cause
GCV resistance, thereby guiding the treatment of HCMV in-
fections.
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